NorthWest Biotherapeutics Inc (NWBO)

[HappyLibrarian]

The news has already been released and unless NWBO is a ten bagger when it comes to increasing their competence level with investor and media it is doubtful that they are going to be able to get a redo on releasing the same data to the public again even if they repackage as TLD. It will be worse if the journal has not gone out by ASCO.

If the data did not attract media attention when released under the NYAS banner for its debut, the media might say ‘old news’ and even ‘failed trial’ if NWBO a controversial corporation releases.

Building credibility and relationships with journalists and media outlets cannot be done at the last minute and by playing the hermit for years, NWBO is not in an easy spot to overcome the bad first impression about our trial data.

The above issues can be overcome but not if NWBO continues to demonstrate they have learned nothing or worse yet, the wrong lessons from the mistakes they’ve made in media and investor relations for years and most recently on May, 10, 2022.